# US 2020/0369763 A1 · Compositions for interferon blockade and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369763 A1
- Document ID: US20200369763A1
- Status: Published application
- Kind: A1
- Application number: 16/766,327
- Filed: 2018-11-21
- Published: 2020-11-26
- Earliest claimed: 2017-12-01
- Assignees: Children's Hospital Medical Center
- Applicants: Children's Hospital Medical Center
- Inventors: Sonata Jodele
- Web page: https://patentgrep.com/patent/US20200369763A1

## CPC

- C07K 16/249: {Interferons}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C07K 16/18: against material from animals or humans
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/158: Expression markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are compositions that may include one or more inhibitors of interferon activity for the treatment of a disease state, for example, a disorder associated with increased interferon levels such as thrombotic microangiopathy (“TMA”). Also disclosed are methods of treating an individual having a disease state such as thrombotic microangiopathy. Further disclosed are methods of diagnosing an individual with TMA.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 8

A method of treating an individual having TMA, comprising the step of administering emapalumab to said individual.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The method of claim 8, wherein said TMA is post-transplant TMA, pregnancy associated TMA, TMA secondary to severe inflammation, TMA secondary to cytokine storm syndrome (CRS) due to chimeric antigen receptor T cell (CART) therapy, or combinations thereof.

### Claim 11 (depends on 8)

The method of claim 8, wherein said TMA is characterized by having one or both of
a. a histological TMA diagnosis in tissue biopsy; and
b. four or markers selected from
i. LDH above normal value for age,
ii. schistocytes on peripheral blood smear,
iii. de novo thrombocytopenia or required platelet transfusions,
iv. de novo anemia or required RBC transfusions,
v. hypertension >99% for age (<18 y of age) or 14/90 (>18 y of age) or receiving antihypertensive therapy;
vi. proteinuria ≥30 mg/dL on random urinalysis ×2 or random urine protein creatinine ratio >1 mg/mg; and
vii. terminal complement activation, characterized by elevated plasma sC5b-9 above normal limit of (≥24 4ng/m1).

### Claim 12 (depends on 8)

The method of claim 8, wherein said TMA is high risk TMA and is characterized by having proteinuria ≥30 mg/dL on random urinalysis ×2 or random urine protein creatinine ratio >1 mg/mg; and terminal complement activation, characterized by elevated plasma sC5b-9 above normal limit of (≥244 ng/ml).

### Claim 13 (depends on 8)

The method of claim 8 wherein said TMA is associated with or secondary to a disease or condition selected from post-organ transplant, pregnancy, severe inflammation, cytokine storm syndrome (CRS) due to chimeric antigen receptor T cell (CART) therapy, solid organ transplant, rheumatologic disease, kidney disease, vasculitis in a rheumatologic disease, liver failure, neuro-degenerative disorder, toxic injury (for example, spider bite, snake bite, toxin ingestion, chemotherapy), metastatic cancer, sepsis, eclampsia/HELLP syndrome, lupus, hemophagocytic lymphohistiocytosis (HLH), sickle cell disease (SCD) with vaso-occlusive cirises, veno-occlusive disease of liver (VOD or sinusoidal obstruction syndrome (SOS)), diffuse alveolar hemorrhage (DAH), idiopathic pneumonia syndrome (IPS), or combinations thereof.

### Claim 14 (depends on 8)

The method of claim 8, further comprising the step of administering a complement blocker.

### Claim 15

A method of treating an individual suspected of having a disorder associated with increased interferon levels, comprising the steps of
a. detecting a level of a marker selected from an interferon or a interferon gamma induced chemokine, or wherein said interferon gamma induced chemokine is selected from CXCL9, CXCL10, CXCL11, or combinations thereof;
b. administering an interferon blocker to said individual when said blood level is increased as compared to a predetermined level.

### Claim 16 (depends on 15)

The method of claim 15 wherein said individual further presents with one or more symptoms of TMA.

### Claim 17 (depends on 15)

The method of claim 15 wherein said individual is diagnosed with TMA.

### Claim 18 (depends on 15)

The method of claim 15, wherein said marker level is determined in a blood sample obtained from said individual.

### Claim 19 (depends on 15)

The method of claim 15, wherein said marker level is determined in a tissue sample obtained from said individual.

### Claim 20 (depends on 15)

The method of claim 15, wherein said marker is free IFNγ, and said predetermined level is a level of an individual that does not have a disorder associated with increased interferon levels

### Claim 21 (depends on 20)

The method of claim 20, wherein said predetermined level is 17 pg/mL.

### Claim 22 (depends on 15)

The method of claim 15, wherein said marker is selected from IFNγ induced chemokines CXCL9, CXCL10, CXCL11, or a combination thereof, wherein said individual is administered an IFNγ blocker where an increase in said marker is detected as compared to a normal control.

### Claim 23 (depends on 15)

The method of claim 15, further comprising administering a complement inhibitor, preferably eculizumab.

### Claim 24

A method of diagnosing an individual with TMA, comprising the step of detecting IFNγ, CXCL9, CXCL10, CXCL11, or a combination thereof, wherein when said level of IFNγ, CXCL9, CXCL10, CXCL11, or combination thereof is increased compared to a control value, said individual is diagnosed with a disorder selected from TMA, preferably TMA associated with or secondary to a disease or condition selected from post-organ transplant, pregnancy, severe inflammation, cytokine storm syndrome (CRS) due to chimeric antigen receptor T cell (CART) therapy, solid organ transplant, rheumatologic disease, kidney disease, vasculitis in a rheumatologic disease, liver failure, neuro-degenerative disorder, toxic injury (for example, spider bite, snake bite, toxin ingestion, chemotherapy), metastatic cancer, sepsis, eclampsia/HELLP syndrome, lupus, hemophagocytic lymphohistiocytosis (HLH), sickle cell disease (SCD) with vaso-occlusive cirises, veno-occlusive disease of liver (VOD or sinusoidal obstruction syndrome (SOS)), diffuse alveolar hemorrhage (DAH), idiopathic pneumonia syndrome (IPS), or combinations thereof.
